As of May 2021 Iperion Life Sciences Consultancy will become a Deloitte business. By combining our specialist industry knowledge and passion for our cause with Deloitte’s network and expertise, we hope to make a greater contribution to the accelerated approval of new or improved medicines as well as the provision of high-quality information to patients and the healthcare sector.

Our commitment to promote data standardization for better patient outcomes

Six years ago, we started Iperion with ambitions to boost innovation in Life Sciences by promoting the structuring and digitizing of regulated data required for the approval and monitoring of medicines. – not only to accelerate speed to market, but to enable greater global collaboration based on reliable, consistent and globally comparable information about medicinal products.

Looking back, we feel privileged to see how we have been able to influence change. We have supported many marketing authorization holders in their efforts to optimize their processes, systems and data quality in regulatory information management. We have worked alongside many of these companies in their assessments and implementation journeys towards ISO IDMP compliance and data interoperability. And we have contributed at a regulatory level to bringing global substance management a step closer to reality.

Our commitment to data interoperability and standardization is in our DNA, and includes pro bono contributions to the wider ecosystem, including the IRISS Forum and proactive support of a range of industry associations.

And now we are proud to share with you that Iperion Life Sciences Consultancy will become Iperion – a Deloitte business from May 1. A very exciting development for us and for our clients and ecosystem partners. Deloitte shares our passion and drive in the area of healthcare and life sciences, and being part of this major global consultancy will enable us to deliver even more effectively in line with our ambitions.

Preserving the Iperion DNA

Deloitte has witnessed our success and recognizes the value of our brand in the market, and is keen to build on that during this important next chapter. We will stay focused on deep subject knowledge and experience in regulatory information management developments such as IDMP. We will remain close to our clients as has always been or priority – while providing even greater value. Along with our new colleagues we will now be able to offer a strengthened global presence, increased functional coverage across related regulatory themes, as well as access to a wealth of experience and professionals. We have already partnered with Deloitte on several projects and we are both convinced of the strong cultural fit as well as the synergy between our two organizations.

The business will run as part of Deloitte’s Risk Advisory function. Co-founder Frits Stulp will serve as a partner within the Deloitte Risk operation, and his counterpart Karel Bastiaanssen will stay on as Director for the next few years to support Iperion’s growth. The home base of Iperion will remain in Vlijmen, the Netherlands.

An exciting new chapter

Commenting on the announcement, Frits Stulp said: “Deloitte and Iperion have been collaborating on innovative digitization projects at pharmaceutical companies for years. The integration with Deloitte is a logical next step to further shape the ambitions and growth strategy of both organizations in this area by, among other things, joining our efforts to implement the data standard ISO IDMP”.

 

Iperion co-founder Karel Bastiaanssen added: “In the drive to make a difference in this industry we have identified common core values in Deloitte. This merger is a deliberate step in our mission towards standardized and structured data, leading to improved speed of innovation and information transparency. The goal, ultimately, is better medicines and better information provisioning in the Life Sciences ecosystem.”

Shared ambition

Speaking for Deloitte, Harvey Christophers, Managing Partner at Deloitte Risk Advisory, said: “Standardized product information is a domain Deloitte has been investing in globally as part of its Life Sciences Regulatory practice, particularly in Europe recently – and in the Netherlands specifically – following the move of EMA. Iperion is an expert in the market and we are eager to see what we can deliver together. The knowledge and passion of Iperion’s young team attracted us, in particular. We are joining forces to help our clients do business responsibly, build trust and have a real impact.”

Aida Demneri, Life Sciences & Healthcare Lead Partner at Deloitte Risk Advisory in the Netherlands, added: “Due to the COVID crisis there is an increased urgency to bring effective medicines to market faster. This requires transformation of regulatory practices towards more agile, data-driven digitalization and standardization of information. That is what we will strive to achieve together with Iperion.”

If you have any questions about the acquisition, please don’t hesitate to reach out to us via contact@iperion.com.

 

Note: The entity Iperion Information Systems is not part of the acquisition and will continue to operate as Colbright.